Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype
- PMID: 17210890
- DOI: 10.1212/01.wnl.0000252798.25690.76
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype
Abstract
Background: Pompe disease (acid maltase deficiency, glycogen storage disease type II; OMIM 232300) is an autosomal recessive lysosomal storage disorder characterized by acid alpha-glucosidase deficiency due to mutations in the GAA gene. Progressive skeletal muscle weakness affects motor and respiratory functions and is typical for all forms of Pompe disease. Cardiac hypertrophy is an additional fatal symptom in the classic infantile subtype. c.-32-13T-->G is the most common mutation in adults.
Objective: To delineate the disease variation among patients with this mutation and to define the c.-32-13T-->G haplotypes in search for genotype-phenotype correlations.
Methods: We studied 98 compound heterozygotes with a fully deleterious mutation (11 novel mutations are described) and the common c.-32-13T-->G mutation.
Results: All patients were Caucasian. None had the classic infantile form of Pompe disease. The clinical course varied far more than anticipated (age at diagnosis <1 to 78 years; age at onset: <1 to 52 years). The acid alpha-glucosidase activities in a subset of patients ranged from 4 to 19.9 nmol/mg/h. Twelve different c.-32-13T-->G haplotypes were identified based on 17 single-nucleotide polymorphisms located in the GAA gene. In 76% of the cases, c.-32-13T-->G was encountered in the second most common GAA core haplotype (DHRGEVVT). In only one case was c.-32-13T-->G encountered in the major GAA core haplotype (DRHGEIVT).
Conclusion: Patients with the same c.-32-13T-->G haplotype (c.q. GAA genotype) may manifest first symptoms at different ages, indicating that secondary factors may substantially influence the clinical course of patients with this mutation.
Comment in
-
Enzyme replacement for infantile Pompe disease: the first step toward a cure.Neurology. 2007 Jan 9;68(2):88-9. doi: 10.1212/01.wnl.0000253226.13795.40. Neurology. 2007. PMID: 17210887 No abstract available.
Similar articles
-
Glycogen storage disease type II in Spanish patients: high frequency of c.1076-1G>C mutation.Mol Genet Metab. 2007 Sep-Oct;92(1-2):183-7. doi: 10.1016/j.ymgme.2007.05.011. Epub 2007 Jul 5. Mol Genet Metab. 2007. PMID: 17616415
-
Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations.Neuromuscul Disord. 2007 Jan;17(1):16-22. doi: 10.1016/j.nmd.2006.09.004. Epub 2006 Oct 23. Neuromuscul Disord. 2007. PMID: 17056254
-
Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.Mol Genet Metab. 2012 Nov;107(3):485-9. doi: 10.1016/j.ymgme.2012.09.003. Epub 2012 Sep 7. Mol Genet Metab. 2012. PMID: 23000108
-
The genotype-phenotype correlation in Pompe disease.Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):59-68. doi: 10.1002/ajmg.c.31318. Epub 2012 Jan 17. Am J Med Genet C Semin Med Genet. 2012. PMID: 22253258 Review.
-
Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.Acta Neurol Belg. 2006 Jun;106(2):82-6. Acta Neurol Belg. 2006. PMID: 16898258 Review.
Cited by
-
Late-Onset Pompe Disease with Normal Creatine Kinase Levels: The Importance of Rheumatological Suspicion.Int J Mol Sci. 2023 Nov 3;24(21):15924. doi: 10.3390/ijms242115924. Int J Mol Sci. 2023. PMID: 37958907 Free PMC article.
-
Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.J Inherit Metab Dis. 2015 Mar;38(2):305-14. doi: 10.1007/s10545-014-9707-6. Epub 2014 Apr 9. J Inherit Metab Dis. 2015. PMID: 24715333 Free PMC article.
-
Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts.Mol Ther Methods Clin Dev. 2020 Nov 20;20:227-236. doi: 10.1016/j.omtm.2020.11.011. eCollection 2021 Mar 12. Mol Ther Methods Clin Dev. 2020. PMID: 33426149 Free PMC article.
-
A genetic modifier of symptom onset in Pompe disease.EBioMedicine. 2019 May;43:553-561. doi: 10.1016/j.ebiom.2019.03.048. Epub 2019 Mar 25. EBioMedicine. 2019. PMID: 30922962 Free PMC article.
-
Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.Mol Genet Metab. 2017 Nov;122(3):99-107. doi: 10.1016/j.ymgme.2017.09.008. Epub 2017 Sep 19. Mol Genet Metab. 2017. PMID: 28951071 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous